Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel L Gilstrap is active.

Publication


Featured researches published by Daniel L Gilstrap.


American Journal of Respiratory and Critical Care Medicine | 2013

Patient–Ventilator Interactions. Implications for Clinical Management

Daniel L Gilstrap; Neil R. MacIntyre

Assisted/supported modes of mechanical ventilation offer significant advantages over controlled modes in terms of ventilator muscle function/recovery and patient comfort (and sedation needs). However, assisted/supported breaths must interact with patient demands during all three phases of breath delivery: trigger, target, and cycle. Synchronous interactions match ventilator support with patient demands; dyssynchronous interactions do not. Dyssynchrony imposes high pressure loads on ventilator muscles, promoting muscle overload/fatigue and increasing sedation needs. On current modes of ventilation there are a number of features that can monitor and enhance synchrony. These include adjustments of the trigger variable, the use of pressure versus fixed flow targeted breaths, and a number of manipulations of the cycle variable. Clinicians need to know how to use these modalities and monitor them properly, especially understanding airway pressure and flow graphics. Future strategies are emerging that have theoretical appeal but they await good clinical outcome studies before they become commonplace.


Chest | 2014

Comparative Effectiveness and Safety of Drug Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis

Remy R Coeytaux; Kristine M Schmit; Bryan Kraft; Andrzej S. Kosinski; Alicea M Mingo; Lisa M Vann; Daniel L Gilstrap; Brooke L Heidenfelder; Rowena J Dolor; Douglas C McCrory

BACKGROUND Current treatments for pulmonary arterial hypertension (PAH) have been shown to improve dyspnea, 6-min walk distance (6MWD), and pulmonary hemodynamics, but few studies were designed to compare treatment regimens or assess the impact of treatment on mortality. METHODS We conducted a systematic review to evaluate the comparative effectiveness and safety of monotherapy or combination therapy for PAH using endothelin receptor antagonists, phosphodiesterase inhibitors, or prostanoids. We searched English-language publications of comparative studies that reported intermediate or long-term outcomes associated with drug therapy for PAH. Two investigators abstracted data and rated study quality and applicability. RESULTS We identified 28 randomized controlled trials involving 3,613 patients. We found no studies that randomized treatment-naive patients to monotherapy vs combination therapy. There was insufficient statistical power to detect a mortality difference associated with treatment. All drug classes demonstrated increases in 6MWD when compared with placebo, and combination therapy showed improved 6MWD compared with monotherapy. For hospitalization, the OR was lower in patients taking endothelin receptor antagonists or phosphodiesterase-5 inhibitors compared with placebo (OR, 0.34 and 0.48, respectively). CONCLUSIONS Although no studies were powered to detect a mortality reduction, monotherapy was associated with improved 6MWD and reduced hospitalization rates. Our findings also suggest an improvement in 6MWD when a second drug is added to monotherapy.


Journal of Critical Care | 2012

Predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy☆

Vinciya Pandian; Daniel L Gilstrap; Marek A. Mirski; Elliott R. Haut; Adil H. Haider; David T. Efron; Natalie M. Bowman; Lonny Yarmus; Nasir I. Bhatti; Kent A. Stevens; Ravi Vaswani; David Feller-Kopman

PURPOSE The purpose of the study was to identify the predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy (PDT). MATERIALS AND METHODS Retrospective analysis of data pertaining to adult patients who underwent PDT between July 2005 and June 2008 in an urban, academic, tertiary care medical center was done. Clinical and demographic data were analyzed for 483 patients undergoing PDT via multivariate logistic regression. RESULTS Mortality data were examined at in-hospital, 14, 30, and 180 days postprocedure. Overall mortality rates were 11% at 14 days, 19% at 30 days, and 40% at 180 days. In-hospital mortality was 30%. CONCLUSIONS Patients undergoing PDT have significant short-term mortality with 11% dying within 14 days and an in-hospital mortality rate of 30%. We identified an index diagnosis of ventilator-associated pneumonia and trauma to be associated with a higher survival rate, whereas older age, oncological diagnosis, cardiogenic shock, and ventricular-assist devices were associated with higher mortality. There is significant heterogeneity in both underlying diagnosis and patient outcomes, and these factors should be considered when deciding to perform this procedure and discussed with patients/family members to provide a realistic expectation of potential prognosis.


Clinics in Chest Medicine | 2016

Patient-Ventilator Interactions

Daniel L Gilstrap; John Davies

Ventilatory muscle fatigue is a reversible loss of the ability to generate force or velocity of contraction in response to increased elastic and resistive loads. Mechanical ventilation should provide support without imposing additional loads from the ventilator (dys-synchrony). Interactive breaths optimize this relationship but require that patient effort and the ventilator response be synchronous during breath initiation, flow delivery, and termination. Proper delivery considers all 3 phases and uses clinical data, ventilator graphics, and sometimes a trial-and-error approach to optimize patient-ventilator interactions. Newer modes optimize interactions but await good clinical outcome data before routine use.


Journal of opioid management | 2018

Discharge prescribing of enteral opioids after initiation as a weaning strategy from continuous opioid infusions in the Intensive Care Unit

Bridgette Kram, PharmD, Bcps, Bcccp; Kylie M. Weigel, PharmD, Bcps; PharmD Michelle Kuhrt; Daniel L Gilstrap

OBJECTIVE To evaluate the proportion of patients receiving a hospital discharge prescription for a scheduled enteral opioid following initiation as a weaning strategy from a continuous opioid infusion in the Intensive Care Unit (ICU). DESIGN Retrospective, observational study. SETTING Five adult ICUs at a large, quaternary care academic medical center. PATIENTS Endotracheally intubated, opioid-naive adults receiving a continuous opioid infusion with a concomitant scheduled enteral opioid initiated. Exclusion criteria were receipt of fewer than two enteral opioid doses, documentation of a long-acting opioid as a home medication, the indication for the enteral opioid was not a weaning strategy, death during hospital admission or discharge to hospice. INTERVENTIONS None. MAIN OUTCOME MEASURES The proportion of ICU and hospital survivors who received a discharge prescription for a scheduled enteral opioid, total duration of continuous opioid infusion, duration of continuous opioid infusion after initiation of an enteral opioid therapy, total duration of enteral therapy, ICU and hospital length of stay. RESULTS Of 62 included patients, 19 patients (30.6 percent) received a new prescription for a scheduled enteral opioid at hospital discharge. The median duration of enteral opioid therapy was longer for patients who received a discharge prescription compared to those who did not (20.09 vs 8.89 days, p = 0.02), though the remaining endpoints were not different. CONCLUSIONS Utilizing scheduled enteral opioids as a weaning strategy from continuous opioid infusions may place patients at risk of ICU-acquired physical dependence on opioids.


Annals of Pharmacotherapy | 2018

Predictors of Vasopressin Responsiveness in Critically Ill Adults

Brittainy Allen; Bridgette Kram; Shawn Kram; Jennifer Schultheis; Steven Wolf; Daniel L Gilstrap; Mark L. Shapiro

Background: Vasopressin is commonly used as an adjunct vasopressor in shock. However, response to vasopressin varies among critically ill patients. Objective: To identify patient-specific factors that are associated with vasopressin responsiveness in critically ill adults. Methods: This retrospective, multicenter study included adult patients who were admitted to an intensive care unit (ICU) and received vasopressin for shock. Patients were excluded if they received vasopressin for less than 30 minutes, if vasopressin was initiated prior to ICU arrival, or if an additional vasopressor was initiated within 30 minutes of starting vasopressin. Responsiveness was defined as an increase in mean arterial pressure of ≥10 mm Hg or the ability to taper a concurrent catecholamine vasopressor. Patient-specific factors evaluated in a multivariate analysis included age, gender, ethnicity, body mass index, type of shock, serum pH, Sequential Organ Failure Assessment (SOFA) score, and use of stress-dose steroids. These variables were also evaluated in a subgroup analysis of patients with septic shock. Results: Of 1619 patients screened, 400 patients were included, with 231 identified as vasopressin responsive and 169 as nonresponsive. Vasopressin used as an adjunct vasopressor, as opposed to first line, during shock was the only variable associated with vasopressin responsiveness (odds ratio [OR] = 1.71; 95% CI = 1.10 to 2.65). Among the subgroup of patients with septic shock, female patients had a higher odds of responding than male patients (OR = 2.10; 95% CI = 1.12 to 3.95). Conclusions: Vasopressin initiated as an adjunct vasopressor, as opposed to first-line therapy, was associated with response.


Clinics in Chest Medicine | 2016

Mechanical Ventilator Discontinuation Process

Lingye Chen; Daniel L Gilstrap; Christopher E. Cox

The goal of this article is to discuss approaches to discontinuing invasive mechanical ventilation in a general intensive care unit (ICU) population. It considers approaches in which the clinician expects patient survival, as well as those that do not. Additionally, approaches to acute and chronic critical illness are included.


Archive | 2012

Noninvasive Positive-Pressure Ventilation (NPPV) for Acute Respiratory Failure

John W Williams; Christopher E. Cox; Daniel L Gilstrap; Christian E Castillo; Joseph A. Govert; Njira L Lugogo; Remy R Coeytaux; Douglas C McCrory; Victor Hasselblad; Amanda J McBroom; Rachael Posey; Rebecca Gray; Gillian D Sanders


The Journal of Allergy and Clinical Immunology | 2013

Asthma and the host-microbe interaction

Daniel L Gilstrap; Monica Kraft


Archive | 2013

Pulmonary Arterial Hypertension: Screening, Management, and Treatment

Douglas C McCrory; Remy R Coeytaux; Kristine M Schmit; Bryan Kraft; Andrzej S. Kosinski; Alicea M Mingo; Lisa M Vann; Daniel L Gilstrap; Njira L Lugogo; Brooke L Heidenfelder; Rachael Posey; R Julian Irvine; Karen Pendergast; Rowena J Dolor

Collaboration


Dive into the Daniel L Gilstrap's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rachael Posey

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge